There isn 't much research on this protein but once scientist began to research alpha-synuclein then there will be better understanding of how Gaucher’s works. According to the National Gaucher’s Foundation “the balance of glucocerebroside enzyme and alpha-synuclein may play a critical role in helping the body’s proteins work correctly”(GaucherDisease). This means that having too much of the alpha-synuclein might keep the glucocerebroside enzyme from breaking down glucocerebroside. This could lead to improper protein folding meaning that the unusual folding of in this case alpha-synuclein causes the proteins to cluster together so that it can not preform its job. This improper folding has been linked to trigger early Parkinson’s disease, usually found with Parkinson’s disease or “LBD who also have a GBA gene mutations this accumulations of abnormal proteins degrades the neutrons so they stop working correctly”(Nalls). With this research being conducted it may lead to new investigations with new insight on how to treat Gaucher’s. From recent research this could lead to reducing glucocerebroside by having researchers test large number of chemical compounds to see what can lower the glucocerebroside in Gaucher 's patient’s body. This would conduct research in order to find which a drug that could cross the blood brain barrier, this helps to protect the brain while filtering out medications, if this proves to be successful it could make a new treat for Gaucher’s patients with type 2 or type 3 Gaucher’s. Another treatment that could become possible if enough research was conducted would be using the chaperone gents which if you don’t know is a variety of drugs that help keep proteins properly folded so they are able to work correctly this
There isn 't much research on this protein but once scientist began to research alpha-synuclein then there will be better understanding of how Gaucher’s works. According to the National Gaucher’s Foundation “the balance of glucocerebroside enzyme and alpha-synuclein may play a critical role in helping the body’s proteins work correctly”(GaucherDisease). This means that having too much of the alpha-synuclein might keep the glucocerebroside enzyme from breaking down glucocerebroside. This could lead to improper protein folding meaning that the unusual folding of in this case alpha-synuclein causes the proteins to cluster together so that it can not preform its job. This improper folding has been linked to trigger early Parkinson’s disease, usually found with Parkinson’s disease or “LBD who also have a GBA gene mutations this accumulations of abnormal proteins degrades the neutrons so they stop working correctly”(Nalls). With this research being conducted it may lead to new investigations with new insight on how to treat Gaucher’s. From recent research this could lead to reducing glucocerebroside by having researchers test large number of chemical compounds to see what can lower the glucocerebroside in Gaucher 's patient’s body. This would conduct research in order to find which a drug that could cross the blood brain barrier, this helps to protect the brain while filtering out medications, if this proves to be successful it could make a new treat for Gaucher’s patients with type 2 or type 3 Gaucher’s. Another treatment that could become possible if enough research was conducted would be using the chaperone gents which if you don’t know is a variety of drugs that help keep proteins properly folded so they are able to work correctly this